Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 145Stomach Neoplasms 22Triple Negative Breast Neoplasms 21Inflammatory Breast Neoplasms 14Carcinoma, Hepatocellular 13Esophageal Neoplasms 11Lymphoma, Large B-Cell, Diffuse 7Neoplasms 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Adenocarcinoma Of Esophagus 4Testicular Neoplasms 3Sarcoma 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Non-Muscle Invasive Bladder Neoplasms 3Liver Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Pathologic Complete Response 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2HER2-negative Breast Cancer 2Carcinoma, Adenoid Cystic 2Breast Diseases 2pCR Rate 1Women With Primary Breast Cancer 1

Interventions

Paclitaxel 11Carboplatin 8Radiotherapy 6Cyclophosphamide 6Trastuzumab 5Chemotherapy, Adjuvant 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Epirubicin 3Doxorubicin 3Cryosurgery 3Cisplatin 3pertuzumab 2Surgical Procedures, Operative 2Radiotherapy, Conformal 2Radiation 2Letrozole 2Lapatinib 2Cryotherapy 2Brachytherapy 2talimogene laherparepvec 1sargramostim 1ferric carboxymaltose 1atezolizumab 1aldesleukin 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Zoledronic Acid 1Vorinostat 1VPS Coriolus versicolor extract 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Ductal, Breast × Epirubicin × Clear all
NCT02682693 2021-02-02

GeparX

GBG Forschungs GmbH

Phase 2 Completed
780 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

RenJi Hospital

Phase 3 Unknown
290 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡